| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioNTech SE | Pumitamig - (China trial/ROSETTA HCC-206) | 1L HCC | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | BNT327-02 | 1-2L Metastatic Triple-negative breast cancer (TNBC) | Phase 2 | Data Released | Intravenous | Oncology |
| BioNTech SE | Autogene cevumeran (BNT122/RO7198457) | Adjuvant ctDNA+ stage II (high risk) / stage III colorectal cancer (CRC) | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | BNT327-06 | First line NSCLC | Phase 2/3 | Enrollment Initiation | Intravenous | Oncology |
| BioNTech SE | Bivalent BNT162b2 | Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine | Phase 2/3 | Ongoing | Intramuscular | COVID-19 |
| BioNTech SE | BNT161 | Influenza Vaccine | Phase 3 | Intramuscular | Immunology | |
| BioNTech SE | Autogene cevumeran (BNT122) | 1L Metastatic Melanoma | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | Trastuzumab pamirtecan (T-Pam) | 2L+ HER2-expressing endometrial cancer | Phase 2 | Ongoing | Intravenous | Oncology |